Interesting. I do note in the limitations two things:
1. in the canaloplasty group, there was a higher number of secondary glaucoma patients, but no mention of the percentage. What if over half were? Seems to be quite a serious limitation to the results.
2. A large number of patients that had the canaloplasty surgery did not return for the follow-up check (likely due to success and no complications), and then removed from the study - resulting a lower percentage of success. I believe it was 30 - if 20 had been successful, the whole thesis is weakened considerably.
Let me know if I have misunderstood the impact of those limitations of the study.
- Forums
- ASX - By Stock
- EYE
- Nova Eye Medical (EYE) Discussion
Nova Eye Medical (EYE) Discussion, page-898
-
-
- There are more pages in this discussion • 2,290 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add EYE (ASX) to my watchlist
|
|||||
Last
22.5¢ |
Change
-0.005(2.17%) |
Mkt cap ! $52.68M |
Open | High | Low | Value | Volume |
23.0¢ | 23.0¢ | 22.5¢ | $36.73K | 161.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 200860 | 22.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
23.0¢ | 75000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 200860 | 0.220 |
1 | 20000 | 0.215 |
6 | 231583 | 0.210 |
6 | 104536 | 0.205 |
14 | 132779 | 0.200 |
Price($) | Vol. | No. |
---|---|---|
0.230 | 75000 | 2 |
0.235 | 9972 | 1 |
0.240 | 7293 | 2 |
0.250 | 227593 | 5 |
0.255 | 125000 | 2 |
Last trade - 15.35pm 22/08/2024 (20 minute delay) ? |
Featured News
EYE (ASX) Chart |
The Watchlist
SS1
SUN SILVER LIMITED
Gerard O'Donovan, Executive Director
Gerard O'Donovan
Executive Director
SPONSORED BY The Market Online